Clinical Remission News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®

- AbbVie will present 15 abstracts, including three oral presentations, in Crohn s disease and ulcerative colitis reinforcing AbbVie s commitment to advancing.

United statesAnn gastroenterolGastroenterol hepatolAndrew anisfeldNational institute of diabetesInternational organization for the studyExchange commissionCrohn colitis foundationBoehringer ingelheimEuropean medicines agencyAmerican gastroenterological associationHealth economics cost of illnessSociety for surgery of the alimentary tractAbbvie incAmerican society for gastrointestinal endoscopyDrug administration

Marla Dubinsky, MD: Clinical Outcomes with Risankizumab Versus Ustekinumab in SEQUENCE

Dubinsky discusses findings from a post-hoc analysis of the head-to-head SEQUENCE trial of risankizumab versus ustekinumab in patients with Crohn disease refractory to anti-TNF therapy.

Marla dubinskyColitis organisation congressDrug administrationEuropean crohnMount sinai kravis childrenUnited european gastroenterology weekInflammatory bowel diseaseCrohn x27s diseaseClinical remissionClinical outcomesAbdominal pain

Risankizumab Achieves Primary Endpoints over Ustekinumab in SEQUENCE Trial

Announced by AbbVie on October 15, 2023, positive results revealed 59% of patients treated with risankizumab and 40% of patients treated with ustekinumab achieved clinical remission, respectively.

Laurent peyrin birouletRoopal thakkarNancy university hospitalImage analysis group laurent peyrin birouletInfinity instituteImage analysis groupUnited european gastroenterology weekNancy universityClinical remissionClinical responseEndoscopic remissionEndoscopic responseCrohn diseaseCrohn x27s diseaseInflammatory bowel disease

Mirikizumab Achieves Primary Endpoints in Phase 3a Trial for Crohn Disease

More than half of patients in the mirikizumab arm achieved clinical remission at week 52.

United kingdomEli lillyDrug administrationSociety for women health research lotus mallbrisHealth researchLotus mallbrisInflammatory bowel diseaseCrohn diseaseCrohn x27s diseaseUlcerative colitisClinical remissionClinical responseEndoscopic responseVivid 1

Relmada Therapeutics (RLMD) Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder

Relmada Therapeutics (RLMD) Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Cedric ogormanRelmada therapeutics incRelmada therapeuticsMajor depressive disorderChief medical officerSustained substantial improvementClinical responseBoth rapidClinical remissionScale also showed clinical improvementClinical global impressionFunctional impairmentSheehan disability scaleHamilton anxiety rating scaleTerm safety